Muscarinic receptor–targeted medicines for schizophrenia
Muscarinic Receptor Activators as Antipsychotic Agents
This project develops drugs that boost specific brain muscarinic receptors to help people with schizophrenia who have hallucinations, low motivation, or trouble thinking clearly.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-11062492 on NIH RePORTER |
What this research studies
Researchers are studying how activating a particular muscarinic receptor (called M1) changes brain circuits in the prefrontal cortex, a region linked to thinking and motivation. They use lab experiments and animal models to see how M1 activation weakens some excitatory signals and strengthens inhibition in the prefrontal cortex, which may counter the overactivity seen early in schizophrenia. The team focuses on highly selective positive allosteric modulators (PAMs) that boost M1 activity without directly turning the receptor on, aiming for fewer side effects. If the lab findings support safety and benefit, this could lead to human studies of new medicines for positive, negative, and cognitive symptoms.
Who could benefit from this research
Good fit: Adults with schizophrenia, especially those with prominent positive symptoms, negative symptoms, or cognitive difficulties, would be the most likely candidates.
Not a fit: People without schizophrenia, those whose symptoms come from other conditions, or patients with medical reasons that prevent use of cholinergic drugs may not benefit.
Why it matters
Potential benefit: Could lead to new medications that better treat hallucinations, low motivation, and thinking problems in schizophrenia.
How similar studies have performed: Early clinical and animal studies of selective muscarinic M1 activators and PAMs have shown promise for improving cognition and some symptoms, but the approach is still emerging.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Rook, Jerri Michelle — Vanderbilt University
- Study coordinator: Rook, Jerri Michelle
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.